Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T12:50:19.647Z.
Calculation as of: 2026-10-06T12:50:19.647Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f621ea2a381ac0066d385c57ed104ff22630177ee14cd635e65ed0429d7856c2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$579.88M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$573.38M
EV/FCF Ratio
N/A
TTM Avg
19.46x
3Y Avg
19.46x
5Y Avg
19.46x
Market Cap
$561.67M
EV/FCF Ratio
N/A
TTM Avg
34.57x
3Y Avg
33.80x
5Y Avg
13.57x
Market Cap
$637.59M
EV/FCF Ratio
N/A
TTM Avg
53.49x
3Y Avg
23.98x
5Y Avg
29.09x
Market Cap
$642.31M
EV/FCF Ratio
1158.35x
TTM Avg
684.49x
3Y Avg
684.49x
5Y Avg
386.65x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $596.36M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | N/A | 19.46x | 19.46x | 19.46x |
| CorMedix Inc. (CRMD)vs › | $569.56M | 1.83x | 8.01x | 10.23x | 10.23x |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | N/A | 34.57x | 33.80x | 13.57x |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | N/A | 370.81x | 370.81x | 370.81x |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | N/A | 53.49x | 23.98x | 29.09x |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | 1158.35x | 684.49x | 684.49x | 386.65x |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
